Association of Pretreatment Neutrophil-to-Eosinophil Ratio with Clinical Outcomes in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Treated with Nivolumab

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/CAAC.21660
   PubMed Web of Science ®Google Scholar
• Mody MD, Rocco JW, Yom SS, Haddad RI, Saba NF. Head and neck cancer. Lancet. 2021;398(10318):2289–2299. doi:10.1016/S0140-6736(21)01550-6
   PubMed Web of Science ®Google Scholar
• Braakhuis BJM, Brakenhoff RH, René Leemans C. Treatment choice for locally advanced head and neck cancers on the basis of risk factors: biological risk factors. Ann Oncol off J Eur Soc Med Oncol. 2012;23(SUPPL. 10). doi:10.1093/ANNONC/MDS299
   Google Scholar
• Ferris RL, Blumenschein G, Fayette J, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016;375(19):1856–1867. doi:10.1056/NEJMoa1602252
   PubMed Web of Science ®Google Scholar
• Burtness B, Harrington KJ, Greil R, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, Phase 3 study. Lancet. 2019;394(10212):1915–1928. doi:10.1016/S0140-6736(19)32591-7
   PubMed Web of Science ®Google Scholar
• Hori R, Shinohara S, Kojima T, et al. Real-world outcomes and prognostic factors in patients receiving nivolumab therapy for recurrent or metastatic head and neck carcinoma. Cancers. 2019;11(9):1317. doi:10.3390/CANCERS11091317
   PubMed Web of Science ®Google Scholar
• Hanai N, Shimizu Y, Kariya S, et al. Effectiveness and safety of nivolumab in patients with head and neck cancer in Japanese real-world clinical practice: a multicenter retrospective clinical study. Int J Clin Oncol. 2021;26(3):494–506. doi:10.1007/s10147-020-01829-0
   PubMed Web of Science ®Google Scholar
• Samstein RM, Lee CH, Shoushtari AN, et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat Genet. 2019;51(2):202–206. doi:10.1038/S41588-018-0312-8
   PubMed Web of Science ®Google Scholar
• Tumeh PC, Harview CL, Yearley JH, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515(7528):568–571. doi:10.1038/NATURE13954
   PubMed Web of Science ®Google Scholar
• Shen X, Zhao B. Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis. BMJ. 2018;362. doi:10.1136/BMJ.K3529
   Web of Science ®Google Scholar
• Sun C, Mezzadra R, Schumacher TN. Regulation and function of the PD-L1 checkpoint. Immunity. 2018;48(3):434–452. doi:10.1016/J.IMMUNI.2018.03.014
   PubMed Web of Science ®Google Scholar
• Lenouvel D, González-Moles MÁ, Ruiz-Ávila I, Gonzalez-Ruiz L, Gonzalez-Ruiz I, Ramos-García P. Prognostic and clinicopathological significance of PD-L1 overexpression in oral squamous cell carcinoma: a systematic review and comprehensive meta-analysis. Oral Oncol. 2020;106:104722. doi:10.1016/J.ORALONCOLOGY.2020.104722
   PubMed Web of Science ®Google Scholar
• Lenouvel D, González-Moles MÁ, Ruiz-Ávila I, et al. Clinicopathological and prognostic significance of PD-L1 in oral cancer: a preliminary retrospective immunohistochemistry study. Oral Dis. 2021;27(2):173–182. doi:10.1111/ODI.13509
   PubMed Web of Science ®Google Scholar
• Vassilakopoulou M, Avgeris M, Velcheti V, et al. Evaluation of PD-L1 expression and associated tumor-infiltrating lymphocytes in laryngeal squamous cell carcinoma. Clin Cancer Res. 2016;22(3):704–713. doi:10.1158/1078-0432.CCR-15-1543
   PubMed Web of Science ®Google Scholar
• Yang WFA, Wong MCM, Thomson PJ, Li KY, Su Y-X. The prognostic role of PD-L1 expression for survival in head and neck squamous cell carcinoma: a systematic review and meta-analysis. Oral Oncol. 2018;86:81–90. doi:10.1016/j.oraloncology.2018.09.016
   PubMed Web of Science ®Google Scholar
• Gavrielatou N, Doumas S, Economopoulou P, Foukas PG, Psyrri A. Biomarkers for immunotherapy response in head and neck cancer. Cancer Treat Rev. 2020;84. doi:10.1016/J.CTRV.2020.101977
   Web of Science ®Google Scholar
• Speirs V. Quality considerations when using tissue samples for biomarker studies in cancer research. Biomark Insights. 2021;16. doi:10.1177/11772719211009513
   Web of Science ®Google Scholar
• Tanizaki J, Haratani K, Hayashi H, et al. Peripheral blood biomarkers associated with clinical outcome in non-small cell lung cancer patients treated with nivolumab. J Thorac Oncol. 2018;13(1):97–105. doi:10.1016/J.JTHO.2017.10.030
   PubMed Web of Science ®Google Scholar
• Lalani AKA, Xie W, Martini DJ, et al. Change in neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma. J Immunother Cancer. 2018;6(1):5. doi:10.1186/S40425-018-0315-0
   PubMed Web of Science ®Google Scholar
• Weide B, Martens A, Hassel JC, et al. Baseline biomarkers for outcome of melanoma patients treated with pembrolizumab. Clin Cancer Res. 2016;22(22):5487–5496. doi:10.1158/1078-0432.CCR-16-0127
   PubMed Web of Science ®Google Scholar
• Chu X, Zhao J, Zhou J, et al. Association of baseline peripheral-blood eosinophil count with immune checkpoint inhibitor-related pneumonitis and clinical outcomes in patients with non-small cell lung cancer receiving immune checkpoint inhibitors. Lung Cancer. 2020;150:76–82. doi:10.1016/J.LUNGCAN.2020.08.015
   PubMed Web of Science ®Google Scholar
• Davis BP, Rothenberg ME. Eosinophils and Cancer. Cancer Immunol Res. 2014;2(1):1–8. doi:10.1158/2326-6066.CIR-13-0196
   PubMed Web of Science ®Google Scholar
• Carretero R, Sektioglu IM, Garbi N, Salgado OC, Beckhove P, Hämmerling GJ. Eosinophils orchestrate cancer rejection by normalizing tumor vessels and enhancing infiltration of CD8(+) T cells. Nat Immunol. 2015;16(6):609–617. doi:10.1038/NI.3159
   PubMed Web of Science ®Google Scholar
• Heppt MV, Heinzerling L, Kähler KC, et al. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition. Eur J Cancer. 2017;82:56–65. doi:10.1016/J.EJCA.2017.05.038
   PubMed Web of Science ®Google Scholar
• Tucker MD, Brown LC, Chen YW, et al. Association of baseline neutrophil-to-eosinophil ratio with response to nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma. Biomark Res. 2021;9(1):1–9. doi:10.1186/S40364-021-00334-4/TABLES/3
   PubMed Web of Science ®Google Scholar
• Martins F, Sofiya L, Sykiotis GP, et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol. 2019;16(9):563–580. doi:10.1038/S41571-019-0218-0
   PubMed Web of Science ®Google Scholar
• Alves A, Dias M, Campainha S, Barroso A. Peripheral blood eosinophilia may be a prognostic biomarker in non-small cell lung cancer patients treated with immunotherapy. J Thorac Dis. 2021;13(5):2716–2727. doi:10.21037/jtd-20-3525
   PubMed Web of Science ®Google Scholar
• Nishikawa D, Suzuki H, Koide Y, et al. Prognostic markers in head and neck cancer patients treated with nivolumab. Cancers. 2018;10(12):466. doi:10.3390/cancers10120466
   PubMed Web of Science ®Google Scholar
• Kiyota N, Hasegawa Y, Takahashi S, et al. A randomized, open-label, Phase III clinical trial of nivolumab vs. therapy of investigator’s choice in recurrent squamous cell carcinoma of the head and neck: a subanalysis of Asian patients versus the global population in checkmate 141. Oral Oncol. 2017;73:138–146. doi:10.1016/j.oraloncology.2017.07.023
   PubMed Web of Science ®Google Scholar
• Mollinedo F. Neutrophil degranulation, plasticity, and cancer metastasis. Trends Immunol. 2019;40(3):228–242. doi:10.1016/J.IT.2019.01.006
   PubMed Web of Science ®Google Scholar
• Xiong S, Dong L, Cheng L. Neutrophils in cancer carcinogenesis and metastasis. J Hematol Oncol. 2021;14(1). doi:10.1186/S13045-021-01187-Y
   Web of Science ®Google Scholar
• Tucker MD ASCO 2021: association between Neutrophil-to-Eosinophil Ratio (NER) and efficacy outcomes in the JAVELIN renal 101 study. Available from: https://www.urotoday.com/conference-highlights/asco-2021/asco-2021-kidney-cancer/130142-asco-2021-association-between-neutrophil-to-eosinophil-ratio-ner-and-efficacy-outcomes-in-The-javelin-renal-101-study.html. Accessed September 20, 2022.
   Google Scholar
• Furubayashi N, Minato A, Negishi T, et al. The association of clinical outcomes with posttreatment changes in the relative eosinophil counts and neutrophil-to-eosinophil ratio in patients with advanced urothelial carcinoma treated with pembrolizumab. Cancer Manag Res. 2021;13:8049–8056. doi:10.2147/CMAR.S333823
   PubMed Web of Science ®Google Scholar
• Templeton AJ, McNamara MG, Šeruga B, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. JNCI J Natl Cancer Inst. 2014;106(6). doi:10.1093/JNCI/DJU124
   Web of Science ®Google Scholar
• Capone M, Giannarelli D, Mallardo D, et al. Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab. J Immunother Cancer. 2018;6(1). doi:10.1186/S40425-018-0383-1
   PubMed Web of Science ®Google Scholar
• Bilen MA, Dutcher GMA, Liu Y, et al. Association between pretreatment neutrophil-to-lymphocyte ratio and outcome of patients with metastatic renal-cell carcinoma treated with nivolumab. Clin Genitourin Cancer. 2018;16(3):e563–e575. doi:10.1016/J.CLGC.2017.12.015
   PubMed Web of Science ®Google Scholar